Correlation of plasma and neuroimaging biomarkers in Alzheimer's disease

被引：11

作者：

Brickman, Adam M. ^{[1
,2
,3
]}

Manly, Jennifer J. ^{[1
,2
,3
]}

Honig, Lawrence S. ^{[1
,2
,3
]}

Sanchez, Danurys ^{[1
,2
,3
]}

Reyes-Dumeyer, Dolly ^{[1
,2
,3
]}

Lantigua, Rafael A. ^{[1
,4
]}

Vonsattel, Jean Paul ^{[1
,4
,5
]}

Teich, Andrew F. ^{[1
,5
]}

Kang, Min Suk ^{[1
]}

Dage, Jeffrey L. ^{[6
,7
]}

Mayeux, Richard ^{[1
,2
,3
]}

机构：

[1] Columbia Univ, Vagelos Coll Phys & Surg, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY 10027 USA

[2] Columbia Univ, Vagelos Coll Phys & Surg, GH Sergievsky Ctr, New York, NY 10027 USA

[3] Columbia Univ, Vagelos Coll Phys & Surg, Dept Neurol, New York, NY USA

[4] New York Presbyterian Hosp, New York, NY USA

[5] Columbia Univ, Vagelos Coll Phys & Surg, Dept Med, New York, NY USA

[6] Columbia Univ, Vagelos Coll Phys & Surg, Dept Pathol & Cell Biol, New York, NY USA

[7] Indiana Univ, Sch Med, Stark Neurosci Res Inst, Indianapolis, IN USA

来源：

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY | 2022年 / 9卷 / 05期

基金：

美国国家卫生研究院;

关键词：

DEMENTIA; TAU;

D O I：

10.1002/acn3.51529

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Blood-based phosphorylated tau (Ptau) 181 and 217 biomarkers are sensitive and specific for Alzheimer's disease. In this racial/ethnically diverse cohort study, participants were classified as biomarker positive (Ptau+) or negative (Ptau-) based on Ptau 181 and 217 concentrations and as cognitively impaired (Sym) or unimpaired (Asym). The four groups, Ptau-/Asym, Ptau+/Asym, Ptau-/Sym, and Ptau+/Sym, differed by age, APOE-4 allele frequency, total tau, neurofilament light chain, and cortical thickness measured by MRI. Our results add to increasing evidence that plasma Ptau 181 and 217 concentrations are valid Alzheimer's disease biomarkers in diverse populations.

引用

下载

页码：756 / 761

页数：6

共 50 条

[1] Correlation between cerebrospinal fluid and neuroimaging biomarkers in Alzheimer's disease
Miguel, R.
Barreira, J.
Baldeiras, I.
Oliveira, C.
Carmo, I.
Alves, L.
EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 588 - 588
[2] Neuroimaging Biomarkers for Alzheimer's Disease
Marquez, Freddie
Yassa, Michael A.
MOLECULAR NEURODEGENERATION, 2019, 14 (1)
[3] Neuroimaging biomarkers in Alzheimer's disease
Nestor, Peter
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
[4] Neuroimaging Biomarkers for Alzheimer’s Disease
Freddie Márquez
Michael A. Yassa
Molecular Neurodegeneration, 14
[5] A review of neuroimaging biomarkers of Alzheimer's disease
Varghese, Tinu
Sheelakumari, R.
James, Jija S.
Mathuranath, P. S.
NEUROLOGY ASIA, 2013, 18 (03) : 239 - 248
[6] The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort
Caroli, A.
Frisoni, G. B.
NEUROBIOLOGY OF AGING, 2010, 31 (08) : 1263 - 1274
[7] Multivariate and univariate neuroimaging biomarkers of Alzheimer's disease
Habeck, Christian
Foster, Norman L.
Perneczky, Robert
Kurz, Alexander
Alexopoulos, Panagiotis
Koeppe, Robert A.
Drzezga, Alexander
Stern, Yaakov
NEUROIMAGE, 2008, 40 (04) : 1503 - 1515
[8] Neuroimaging biomarkers in Alzheimer's disease and other dementias
Villemagne, Victor L.
Chetelat, Gael
AGEING RESEARCH REVIEWS, 2016, 30 : 4 - 16
[9] Neuropathology, Neuroimaging, and Fluid Biomarkers in Alzheimer's Disease
Colvee-Martin, Helena
Parra, Juan Rayo
Gonzalez, Gabriel Antonio
Barker, Warren
Duara, Ranjan
DIAGNOSTICS, 2024, 14 (07)
[10] Functional Performance and Alzheimer's Disease Neuroimaging Biomarkers
Vassilaki, Maria
Aakre, Jeremiah
Kremers, Walter
Mielke, Michelle
Geda, Yonas
Machulda, Mary
Knopman, David
Butler, Lesley
Traber, Martin
Vemuri, Prashanthi
Lowe, Val
Jack, Clifford
Roberts, Rosebud
Petersen, Ronald
NEUROLOGY, 2019, 92 (15)

← 1 2 3 4 5 →